Regeneron Pharmaceuticals (REGN) has seen a surge in stock acquisition by several investments firms such as
Rehmann Capital Advisory Group,
SteelPeak Wealth LLC, and
China Universal Asset Management Co. Ltd. Meanwhile, other organizations including the
Nisa Investment Advisors LLC and
Calamos Advisors LLC have reduced their holdings.
Regeneron's Lynozyfic obtained
accelerated FDA approval for multiple myeloma, strengthening the case for investment in the company.
JP Morgan reaffirmed an $800 price target, however,
UBS lowered theirs. The company's growth has shifted as
Wells Fargo maintains a hold. The excitement around
Regeneron's gene-modified T cell therapy has increased following their launch of a
long-term follow-up study. Regulatory success continues with the sanction of
Dupixent in the US and
accelerated FDA approval for a blood cancer therapy. This has led to diversified opinions among analysts, with forecasts ranging from
Regeneron being the worst blue chip stock to and having a
Discounted Biotech Giant Poised for Pipeline-Driven Growth. Meanwhile, the
Phase 3 trial brings new hope for lymphoma treatment, and the
REGN7544 study promises sepsis-induced hypotension advancement.
Regeneron Pharmaceuticals REGN News Analytics from Tue, 25 Feb 2025 08:00:00 GMT to Sat, 12 Jul 2025 16:53:53 GMT -
Rating 7
- Innovation 5
- Information 7
- Rumor -1
